BBIO Share Price Performance
US$71.39
38.80 (119.05%)
28.6% undervalued intrinsic discount
US$100.05
Fair Value
Price US$71.39
AnalystConsensusTarget US$100.05
Vestra US$100.05
AnalystLowTarget US$80.00
Fair ValueUS$100.05
Share Pricen/a
BridgeBio Pharma, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 36 Fair Values set on narratives written by author
BBIO Community Narratives
AN
Fair Value US$100.05 28.6% undervalued intrinsic discount
Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion
0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
VE
Fair Value US$100.05 28.6% undervalued intrinsic discount
BridgeBio Pharma (BBIO): Orchestrating a Phase 3 Symphony – The Transition from Cash Burn to Commercial Powerhouse.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$80 10.8% undervalued intrinsic discount
Rising Global Price Controls And Costs Will Curb Future Prospects
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
BridgeBio Pharma (BBIO): Orchestrating a Phase 3 Symphony – The Transition from Cash Burn to Commercial Powerhouse.
BridgeBio is currently navigating a "catalyst-rich" season that is fundamentally shifting its identity from a high-risk R&D engine to a diversified commercial entity. Trading at $65.64 as of the March 9, 2026, close, the stock has held remarkably steady, gaining 0.4% today despite a broad-market sell-off that hammered many of its small- and mid-cap biotech peers.Read more
45
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion
Key Takeaways Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins. Efficient commercialization strategy and ample cash reserves support future product launches without requiring immediate equity dilution, strengthening operational leverage.Read more
280
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
AN
US$100.05
28.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
30.4%
Future PE
34.55x
Price in 2029
US$123.49
Rising Global Price Controls And Costs Will Curb Future Prospects
Key Takeaways Heavy reliance on a single lead asset and limited pipeline heightens exposure to regulatory, commercial, and market access risks that could severely impact growth and profitability. High operating expenses and rising competition challenge sustained profitability, while regulatory pressures threaten pricing power and delay future product launches.Read more
16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$80
10.8% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
7.1%
Future PE
143.12x
Price in 2029
US$98.46
Advances In Genomics And AI Will Expand Rare Disease Markets
Key Takeaways BridgeBio's innovative therapies, market access strategy, and late-stage pipeline position it for outsized revenue growth and durable margin expansion beyond analyst expectations. Advances in drug discovery, robust financial partnerships, and a growing patient base support sustained product launches and accelerating earnings growth.Read more
31
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$127.69
44.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
38.43%
Future PE
27.28x
Price in 2029
US$157.47
Trending Discussion
Recently Updated Narratives
VE
BridgeBio Pharma (BBIO): Orchestrating a Phase 3 Symphony – The Transition from Cash Burn to Commercial Powerhouse.
Fair Value: US$100.05 28.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Beyond 2026
Fair Value: US$100.05 28.6% undervalued intrinsic discount
19 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BBIO: Phase 3 Achondroplasia Data And Broad Pipeline Will Shape Next Phase
Fair Value: US$80 10.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BridgeBio Pharma, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -3.74
- 95.82%
- -144.39%
- -89.2%
About BBIO
- Founded
- 2015
- Employees
- 837
- CEO
- WebsiteView website
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
